INTRODUCTION

Ψ
Coagulation and fibrin formation may be viewed as two opposing processes. The first is a procoagulant process that is triggered by the binding of tissue factor to factor VII to form a complex 1 , which in turn initiates a series of reactions ultimately leading to thrombin generation and fibrin clot formation
2
. The latter is an anticoagulant process that originates from thrombin directly via plasma antithrombin (AT) III 3 . A balance between these procoagulant and anticoagulant processes is essential to prevent unwanted thrombin generation under normal physiological conditions. In patients with chronic liver disease, this balance is disrupted. Hemostatic abnormalities in these patients reflect the degree of hepatic dysfunction 4 6 . It is clear that disseminated intravascular coagulation (DIC) involves the activation of the extrinsic coagulation pathway, which is critically dependent on tissue damage specifically to the endothelium. This activation triggers inflammation, increases the circulating levels of a variety of cytokines 7 , and impairs physiological mechanisms of anticoagulation 8 . DIC presents a diagnostic and therapeutic challenge in patients with liver disease.
Various theories propose liver necrosis as a probable triggering event for DIC, because the coagulation profile in DIC is virtually indistinguishable from that seen in advanced liver disease
5
. We studied the correlation between laboratory measurements of coagulation activity in patients with chronic hepatitis, chronic cirrhosis, or no known liver disease, to determine the utility of these biomarker tests in determining whether patients with cirrhosis are more susceptible to DIC.
MATERIALS AND METHODS
The present study included 40 patients who were 30 years of age or older. Patients were categorized in two groups: 20 patients with chronic hepatitis C virus infection (group I), 20 patients with cirrhosis due to viral etiology (group II), and 20 healthy participants (group III). None of the patients were receiving anticoagulant therapy at the time of the study. This study was approved by the local ethics committee. All samples that were collected in the Department of Gastroenterology of the Shalimov Institute (Kiev, Ukraine) were tested in a biochemical laboratory for determination of platelet count (PLT), plasma fibrinogen (Fib), prothrombin time (PT), partial thromboplastin time (PTT), thrombin time (TT), and AT III levels. Hepatic infection in group I was confirmed by enzyme linked immunosorbent assay (ELISA), and cirrhosis in group II was confirmed by liver biopsy. Plasma was obtained from fasting blood samples drawn by venipuncture with Vacutainer ® tubes: for AT III levels, blood was drawn into heparinized tubes, and for coagulation test it was drawn into tubes containing sodium citrate 3.8%. АТ III levels were measured using a chromogenic substrate method with a reactive test-standard, according to the manufacturer's instructions (Technology Standard, Barnaul, Russia). In this assay, thrombin was first added to a diluted plasma solution containing excess heparin; after incubation, a thrombinspecific chromogenic substrate was used to determine AT III concentration photometrically at 405 nm with a photometer (Screen Master Plus, Germany) 9 . Fibrinogen levels were determined by the gravimetric method of Rutberg, a principle method based on Wight clotting after thrombin generation by thromboplastin. Clots were then dried on filter paper and incubated at room temperature for 10-15 minutes
10
. PT was measured by the Quik method
11
, and PTT was measured using the method of Langdell et al 12 with a reactive test-standard (P. Z. Cormay, Lublin, Poland). TT was measured by a clotting-based assay with a reactive test-standard (Human, Wiesbaden, Germany). The thrombin time is simple test, a low potency thrombin is added to undiluted plasma and clot formation is timed 13 . Data are expressed as means ± standard deviation (SD).
Statistical significance between individual samples was determined by Student's t-test, and linear regression analysis was used to examine correlations between various measurements. Statistical analysis was performed using the Statistica Demo version 8 for Microsoft Windows XP Professional (Tulsa, OK, USA). P<0.05 was considered statistically significant.
RESULTS
Group I consisted of 8 male and 12 female patients with a mean age of 44.8 years (range 35-60 years); Group II consisted of 11 male and 9 female patients with a mean age of 43 years (range 38-63 years); group III consisted of 10 male and10 female patients with a mean age of 45.8 years (range 38-52 years). The levels of marker coagulation activity measured in each study group are presented in Table 1 . The physiologically normal ranges for each marker, based on reference values from the laboratory, are 75-140% for AT III, 24-33 sec for PTT, 12-14 sec for PT, and 8-14 sec for TT. The normal plasma concentration range of fibrinogen is 2-4 g/l. In patients with chronic hepatitis, PT and TT were not significantly different from those of healthy participants. All of the other tested measures of coagulation activity were significantly different between the patients in both Groups I and II, and the healthy participants. Table 2 shows statistical tests of means against reference constants, regression and correlations for the coagulation activity in each study group.
DISCUSSION
Chronic liver disease is a cause of abnormal hemostasis tests, with results that may include thrombocytopenia and impaired platelet function, or low plasma levels of coagulation factors. There is also evidence that fibrinolytic activity is heightened in chronic liver disease, with the implication that the fibrinolytic system contributes to the derangement of hemostasis through an increased tendency to lyse formed clots. Evidence shows that abnormalities in hemostasis tests are associated with an increased bleeding tendency; however, patients with liver disease do not have bleeding patterns like those of patients who have coagulation factor deficiencies 14 20 . In this study, the level of АТ III in plasma was lower in patients with liver disease in comparison to those in healthy participants (P< 0.05).
A 1989 report evaluated platelet counts, fibrinogen degradation products (FDPs), specifically D-dimer, by latex agglutination, fibrinogen concentration, and TT in a prospective study of patients with DIC 21 . Further, the absence of thrombocytopenia causes portal hypertension in liver disease 22 and excludes the diagnosis of DIC. On the other hand, a low platelet count lacks specificity, as it may be due to an underlying disease, such as sepsis 8 . In our study, platelet counts in patients with either liver disease were comparable to those in healthy participants. As pointed out by Lisman et Although the thrombin generation test was used by Tripodi as a more global test of coagulation than the routine tests such as the PT, their test measures thrombin generation in platelet rich plasma, which more closely represents physiological conditions 23 .
CONCLUSION
Attempts have been made to evaluate the role of hemostatic agents in the management of the most frequent problems of patients with severe liver disease: bleeding and thrombosis. Laboratory diagnosis of these conditions is difficult, because many laboratory tests lack sensitivity and specificity. However, our data show that results of coagulation activity tests were significantly lower in patients with either liver disease were comparable to those in healthy participants and suggest that cirrhosis patients may be more susceptible to DIC. Thus, the measurement of markers for coagulation activity may be valuable in evaluating the risk of DIC in patients with cirrhosis.
